Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.83 |
| ▸ | MTOR | P42345 | 1/20 | 0.83 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.52 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31718274 | 1.00 | TGFBR1 (0.83) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL373474 | 0.91 | TGFBR1 (1.00) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL29361209 | 0.91 | TGFBR1 (1.00) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6178216 | 0.85 | TGFBR1 (0.62) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6228248 | 0.81 | TGFBR1 (0.56) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL23217899 | 0.80 | TGFBR1 (0.56) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL5084560 | 0.80 | TGFBR1 (0.54) | TGFBR1MTORMAPK14 | |
| SCHEMBL6762324 | 0.80 | TGFBR1 (0.80) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL23217896 | 0.80 | TGFBR1 (0.55) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL7550981 | 0.79 | TGFBR1 (0.54) | TGFBR1MTORMAPK14RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | claimed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | claimed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | claimed |
| EP-3907279-A1 | NOVEL GLIA-LIKE CELLS DIFFERENTIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2021-11-10 | — | — | EP | claimed |
| WO-2018160028-A1 | MEDIUM COMPOSITION FOR NEURON DIFFERENTIATION AND METHOD FOR DIFFERENTIATING SOMATIC CELLS INTO NEURONS USING SAME MEDIUM COMPOSITION | 주식회사 셀라토즈테라퓨틱스 | 2018-09-07 | — | — | WO | claimed |
| WO-2018155913-A1 | METHOD FOR DIFFERENTIATION INTO SKELETAL MUSCLE CELL USING LOW-MOLECULAR WEIGHT COMPOUND | 성균관대학교산학협력단 | 2018-08-30 | — | — | WO | claimed |
| US-20240093147-A1 | GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2024-03-21 | — | — | US | disclosed |
| US-20230364153-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | Research & Business Foundation Sungkyunkwan University (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11801304-B2 | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof | NAMMI THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | Cellapeutics Bio (KR) | 2022-06-16 | — | — | US | disclosed |
| WO-2022065859-A1 | METHOD FOR DIRECT REPROGRAMMING FROM SOMATIC CELLS INTO PANCREATIC BETA CELLS BY USING MICRORNA, AND DIFFERENTIATION COMPOSITION | 성균관대학교산학협력단 | 2022-03-31 | — | — | WO | disclosed |
| US-20210015807-A1 | ALK5 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | CYTOO (FR) | 2021-01-21 | — | — | US | disclosed |
| WO-2020242212-A1 | NOVEL COCKTAIL COMPOSITION FOR PRODUCING PSEUDO-GLIAL CELL, NOVEL PSEUDO-GLIAL CELL PRODUCED USING SAME, METHOD FOR PRODUCING SAME, AND CELL THERAPEUTIC AGENT CONTAINING SAME FOR PREVENTING OR TREATING NEUROLOGICAL DISEASES | 성균관대학교산학협력단 | 2020-12-03 | — | — | WO | disclosed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON RESEARCH, LTD. (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2011-06-30 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | US | disclosed |
| WO-2007070866-A2 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALCON, INC. (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115870-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MTOR 1379/4885MAPK14 890/4885 |
| US-20110160210-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MTOR 1379/4885MAPK14 890/4885 |
| US-20220186183-A1 | NOVEL GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | GMFG, HGF, BDNF | TGFBR1 2424/4885MTOR 3097/4885MAPK14 2736/4885 |
| US-20070142376-A1 | CONTROL OF INTRAOCULAR PRESSURE USING ALK5 MODULATION AGENTS | ALK, ACVR1, ACVR2A | TGFBR1 14/4885MTOR 1379/4885MAPK14 890/4885 |
| US-20240093147-A1 | GLIA-LIKE CELLS DIFFERENATIATED FROM SOMATIC CELLS, PREPARATION METHOD THEREFOR, COCKTAIL COMPOSITION FOR PREPARING SAME, CELL THERAPEUTIC AGENT FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME, AND METHOD FOR PREVENTING AND TREATING NEUROLOGICAL DISORDERS BY ADMINISTERING SAME | MIF, BDNF, HGF | TGFBR1 1419/4885MTOR 1605/4885MAPK14 815/4885 |
| US-11801304-B2 | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof | TBC1D5, FABP5, PLIN5 | TGFBR1 933/4885MTOR 1643/4885MAPK14 3661/4885 |
| US-20210015807-A1 | ALK5 INHIBITORS AS SKELETAL MUSCLE HYPERTROPHY INDUCERS | MUSK, MSTN, ACVRL1 | TGFBR1 45/4885MTOR 739/4885MAPK14 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.